Fluidigm Corporation (NASDAQ: FLDM) is one of 18 publicly-traded companies in the “Medical Software & Technology Services” industry, but how does it contrast to its peers? We will compare Fluidigm Corporation to related companies based off the strength of its analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Profitability

This table compares Fluidigm Corporation and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fluidigm Corporation -74.05% -121.04% -18.55%
Fluidigm Corporation Competitors -18.37% -12.06% -2.29%

Valuation and Earnings

This table compares Fluidigm Corporation and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Fluidigm Corporation $96.72 million -$62.62 million -2.17
Fluidigm Corporation Competitors $375.89 million $34.57 million 9.62

Fluidigm Corporation’s peers have higher revenue and earnings than Fluidigm Corporation. Fluidigm Corporation is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently the more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and price targets for Fluidigm Corporation and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fluidigm Corporation 0 0 1 0 3.00
Fluidigm Corporation Competitors 111 477 785 16 2.51

Fluidigm Corporation currently has a consensus price target of $9.00, suggesting a potential upside of 68.86%. All “Medical Software & Technology Services” companies have a potential upside of 16.65%. Given Fluidigm Corporation’s stronger consensus rating and higher possible upside, equities analysts plainly believe Fluidigm Corporation is more favorable than its peers.

Risk and Volatility

Fluidigm Corporation has a beta of 3.36, meaning that its share price is 236% more volatile than the S&P 500. Comparatively, Fluidigm Corporation’s peers have a beta of 1.33, meaning that their average share price is 33% more volatile than the S&P 500.

Insider & Institutional Ownership

88.9% of Fluidigm Corporation shares are owned by institutional investors. Comparatively, 63.2% of shares of all “Medical Software & Technology Services” companies are owned by institutional investors. 4.7% of Fluidigm Corporation shares are owned by company insiders. Comparatively, 22.1% of shares of all “Medical Software & Technology Services” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Fluidigm Corporation peers beat Fluidigm Corporation on 7 of the 12 factors compared.

Fluidigm Corporation Company Profile

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.

Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.